IGF::OT::IGF SBIR PHASE I TOPIC 331: BIOPSY GUIDANCE WITH COHERENT RAMAN SPECTROSCOPY

IGF::OT::IGF SBIR 第一阶段主题 331：使用相干拉曼光谱进行活检指导

• 批准号: 8945569
• 负责人: CHRISTIAN FREUDIGER
• 金额: $ 22.43万
• 依托单位: INVENIO IMAGING INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-22 至 2015-06-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8945569
• 关键词: Biological Preservation; Biological Tumor Markers; Biopsy; Brain; Contracts; Devices; Diagnosis; Diagnostic; Epidermal Growth Factor Receptor; Fiber Optics; Future; Glioma; Human Resources; Image Analysis; Infiltration; Lasers; Malignant Neoplasms; Malignant neoplasm of brain; Measures; Methodology; Modeling; Molecular Analysis; Molecular Profiling; Needle biopsy procedure; Patients; Phase; Procedures; Quality Control; Raman Spectrum Analysis; Rattus; Risk; Safety; Sampling; Side; Small Business Innovation Research Grant; Specimen; Spectrum Analysis; Staining method; Stains; Techniques; Time; Tissues; Training; Writing; cancer cell; cost; density; in vivo; miniaturize; quality assurance; sensor; thiobarbituric acid; tumor

This contract will develop a miniaturized fiber-optic probe for coherent Raman scattering (CRS) spectroscopy that fits inside a standard biopsy needle and allows real-time guidance toward tissue with a high density of malignant cells, which would be biopsied for molecular analysis while sparing uninvolved tissue. CRS is a non-destructive and highly sensitive laser spectroscopy technique for in vivo molecular profiling. Accuracy, safety and in vivo biopsy guidance will be demonstrated in a brain cancer (glioma) rat model and can be extended to other cancers in the future. It is anticipated that this approach can reduce the number of repeat biopsies required to obtain samples for diagnosis with emerging molecular profiling techniques and thus reduce cost and risk to patients.

该合同将开发一种用于相干拉曼散射（CRS）光谱的小型光纤探头，该探头安装在标准活检针内，并允许对具有高密度恶性细胞的组织进行实时引导，该组织将进行活检以进行分子分析，同时保留未涉及的组织。CRS是一种非破坏性和高灵敏度的激光光谱技术，用于体内分子分析。准确性，安全性和体内活检指导将在脑癌（神经胶质瘤）大鼠模型中得到证明，并可在未来扩展到其他癌症。预计这种方法可以减少获得用于新兴分子谱分析技术诊断的样本所需的重复活检次数，从而降低患者的成本和风险。